Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

September 2023 in “ Dermatology and Therapy ”

Susan C. Taylor, Neil J. Korman, Tsen‐Fang Tsai, Yutaka Shimomura, Meghan Feely, Yves Dutronc, Wen‐Chi Wu, Najwa Somani, Antonella Tosti

Baricitinib JAK1 inhibitor JAK2 inhibitor alopecia areata SALT score scalp hair growth

TLDR Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

The document is a post-hoc analysis of two phase 3 trials, BRAVE-AA1 and BRAVE-AA2, involving 855 patients, studying the efficacy of Baricitinib, an oral JAK1/JAK2 inhibitor, in treating severe alopecia areata (AA). The study found that both 2 mg and 4 mg doses of Baricitinib improved scalp hair growth up to week 52. Patients with a Severity of Alopecia Tool (SALT) score of 50-94 responded better than those with a score of 95-100. The 4 mg dose resulted in a faster and higher response rate than the 2 mg dose. However, patients with a baseline SALT score of 95-100 had a longer response time to treatment. The study concluded that the baseline severity of hair loss should be considered when setting expectations about treatment response.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations, March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Alopecia Areata: Current Understanding and Management

11 citations, January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft”

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

research Rethinking The Classification Of Alopecia Areata

13 citations, February 2019 in “Journal of the American Academy of Dermatology”

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

The Medical and Psychosocial Associations of Alopecia: Recognizing Hair Loss as More Than a Cosmetic Concern

Related Research

1 / 1 results

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child

April 2019 in “International journal of research in dermatology”

A child with rough nails also had hair loss and allergies.

Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

Research cited in this study

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

research Alopecia Areata: Current Understanding and Management

research Rethinking The Classification Of Alopecia Areata

research The Medical and Psychosocial Associations of Alopecia: Recognizing Hair Loss as More Than a Cosmetic Concern

research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

Related Community Posts Join

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

community Anyone heard of or have experience using baricitinib?

community Olumiant active ingredient Baricitinib

community Lilly to seek first approval of an autoimmune drug for hair loss

community Does a minoxidil tester exist? To test if whatever you get is actually minoxidil or some fake?

community I am a dermatologist with a clinical interest in alopecia. AMA

Related Research

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child